CSS LLC/IL - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 196 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.

Quarter-by-quarter ownership
CSS LLC/IL ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2022$162,000
-79.5%
10,000
-79.4%
0.01%
-78.6%
Q4 2021$791,000
+110.4%
48,500
+197.5%
0.03%
+86.7%
Q1 2021$376,000
-74.6%
16,300
-72.8%
0.02%
-73.7%
Q4 2020$1,478,000
+6.9%
59,847
+79.4%
0.06%
-13.6%
Q3 2020$1,383,000
-15.2%
33,364
-1.9%
0.07%
-28.3%
Q2 2020$1,630,000
+3.6%
34,000
+36.0%
0.09%
-25.8%
Q1 2020$1,573,000
-65.9%
25,000
-32.9%
0.12%
-51.6%
Q4 2019$4,616,000
+737.7%
37,247
+348.8%
0.26%
+631.4%
Q3 2019$551,000
+109.5%
8,300
+151.5%
0.04%
+133.3%
Q2 2019$263,000
-81.4%
3,300
-73.9%
0.02%
-82.1%
Q1 2019$1,417,000
-2.5%
12,660
-49.2%
0.08%
+16.7%
Q4 2017$1,454,000
+4.5%
24,900
+3.8%
0.07%
+5.9%
Q3 2017$1,392,000
-14.9%
24,000
+77.8%
0.07%
-13.9%
Q2 2017$1,635,000
+23.5%
13,500
+15.4%
0.08%
-1.2%
Q1 2017$1,324,000
+143.8%
11,700
+134.0%
0.08%
+166.7%
Q4 2016$543,0005,0000.03%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2020
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$14,787,0002.73%
DeepCurrents Investment Group LLC 416,800$9,620,0000.33%
DUALITY ADVISERS, LP 105,668$2,439,0000.21%
EULAV Asset Management 335,000$7,732,0000.21%
Virtus ETF Advisers LLC 19,375$447,0000.19%
Hennion & Walsh Asset Management, Inc. 135,214$3,121,0000.19%
PDT Partners, LLC 110,592$2,552,0000.18%
KETTLE HILL CAPITAL MANAGEMENT, LLC 70,256$1,622,0000.16%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$3,896,0000.12%
WOODWARD DIVERSIFIED CAPITAL, LLC 8,939$206,0000.12%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders